ZBIO — Zenas Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $2.18bn
- $1.96bn
- $5.00m
Annual cashflow statement for Zenas Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -119 | -37.1 | -157 |
| Depreciation | |||
| Non-Cash Items | 45.6 | 14.5 | 11.7 |
| Unusual Items | |||
| Purchased R&D | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | 7.97 | -8.04 | 25.4 |
| Change in Prepaid Expenses | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Cash from Operating Activities | -65.7 | -30.5 | -120 |
| Capital Expenditures | -2.2 | -0.017 | -0.131 |
| Purchase of Fixed Assets | |||
| Purchase / Acquisition of Intangibles | |||
| Other Investing Cash Flow Items | — | — | -30.4 |
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Cash from Investing Activities | -2.2 | -0.017 | -30.6 |
| Financing Cash Flow Items | — | — | -6.33 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | 59.4 | 20.1 | 413 |
| Foreign Exchange Effects | |||
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | -8.5 | -10.4 | 263 |